PMID: 3537615Jan 1, 1986Paper

Immunotherapy in the poisoned patient. Overview of present applications and future trends

Medical Toxicology
J B Sullivan

Abstract

Immunotherapy for reversal of toxicity due to poisons and drugs is not new. However, refinements in antibody isolation and purification as well as the advancement of hybridoma technology and recombinant DNA biotechnology has led to a new generation of immunotherapeutic and diagnostic agents. The advent of monoclonal antibody technology in 1975 heralded the new age of immunopharmacology and immunotoxicology. Monoclonal antibodies designed for a specific antigen resolved the problem of polyclonality and cross-reactivity of traditional antibodies. Along with the production and isolation of active antibody fragments from both polyclonal and human monoclonal sources, as well as the ability to tailor-make chimeric antibodies by recombinant biotechnology, the development of novel immunotherapeutic agents has taken place. Two immunotherapeutic modalities, digoxin-specific antibody fragments (Fab) and snake antivenin, have been available for the clinician's armamentarium for years. Along the same lines of anti-digoxin Fab development, application of newer antibody isolation technology has led to a purified IgG(T) antibody for snake venom poisoning which is still in the developmental stages. Potential future developments in immunotherape...Continue Reading

References

Apr 8, 1976·The New England Journal of Medicine·T W SmithV P Butler
Aug 1, 1975·Annals of Internal Medicine·B ZweimanE A Hildreth
Jan 1, 1985·The American Journal of Tropical Medicine and Hygiene·F E RussellD Bar-Or
Sep 20, 1985·Science·S L Morrison
Jan 1, 1985·Toxicon : Official Journal of the International Society on Toxinology·R R NewJ Friend
Sep 1, 1972·The Journal of Experimental Medicine·M KalinerK F Austen
Jan 1, 1967·Proceedings of the National Academy of Sciences of the United States of America·V P Butler, J P Chen
Jan 1, 1973·Advances in Immunology·V P Butler, S M Beiser
Oct 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·J CurdE Haber
Apr 1, 1966·The American Journal of Cardiology·W S HarrisA M Weissler
Jul 1, 1966·The Biochemical Journal·R C Weir, R R Porter
Aug 1, 1981·The Journal of Allergy and Clinical Immunology·R L JacobsC H Beckmann
Jan 1, 1981·Annual Review of Pharmacology and Toxicology·J C Foreman
Jul 1, 1983·Biochemical Pharmacology·E Haber
Nov 29, 1984·The New England Journal of Medicine·T J LawleyM M Frank
Jan 1, 1983·Toxicon : Official Journal of the International Society on Toxinology·M IsmailM E Abdullah
Jan 1, 1984·Annual Review of Pharmacology and Toxicology·H B Matthews, R L Dedrick
Jan 1, 1984·Toxicon : Official Journal of the International Society on Toxinology·N B Egen, F E Russell
Nov 8, 1984·The New England Journal of Medicine·A L Sheffer
Apr 1, 1984·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·D E LenzT R Clow
Nov 1, 1980·The Journal of Clinical Investigation·P L SmithL M Lichtenstein
Mar 19, 1964·The New England Journal of Medicine·L P JAMES, K F AUSTEN

❮ Previous
Next ❯

Citations

Aug 11, 2011·Journal of Veterinary Emergency and Critical Care·Michael E PetersonKevin Fitzgerald
Nov 24, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Robert J Flanagan, Alison L Jones
Jan 1, 1991·Journal of Toxicology. Clinical Toxicology·J B LeikinD O Hryhorczuk
Oct 23, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Elizabeth M LaurenzanaS Michael Owens
Jan 1, 1989·Journal of Toxicology. Clinical Toxicology·J M ScherrmannJ M Bourre
Jul 1, 1990·Toxicology and Applied Pharmacology·N TerrienJ M Scherrmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.